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Abstract
Anti-resorptive and anabolic treatments can be used sequentially to treat osteoporosis, but their effects on bone composition 
are incompletely understood. Osteocytes may influence bone tissue composition with sequential therapies because bisphos-
phonates diffuse into the canalicular network and anabolic treatments increase osteocyte lacunar size. Cortical bone composi-
tion of osteopenic, ovariectomized (OVX) rats was compared to that of Sham-operated rats and OVX rats given monotherapy 
or sequential regimens of single approved anti-osteoporosis medications. Adult female Sprague–Dawley rats were OVX 
(N = 37) or Sham–OVXd (N = 6). After 2 months, seven groups of OVX rats were given three consecutive 3-month periods 
of treatment with vehicle (V), h-PTH (1–34) (P), alendronate (A), or raloxifene (R), using the following orders: VVV, PVV, 
RRR, RPR, AAA, AVA, and APA. Compositional properties around osteocyte lacunae of the left tibial cortex were assessed 
from Raman spectra in perilacunar and non-perilacunar bone matrix regions. Sequential treatments involving parathyroid 
hormone (PTH) caused lower mean collagen maturity relative to monotherapies. Mean mineral:matrix ratio was 2.2% greater, 
mean collagen maturity was 1.4% greater, and mean carbonate:phosphate ratio was 2.2% lower in the perilacunar than in 
the non-perilacunar bone matrix region (all P < 0.05). These data demonstrate cortical bone tissue composition differences 
around osteocytes caused by sequential treatment with anti-osteoporosis medications. We speculate that the region-specific 
differences demonstrate the ability of osteocytes to alter bone tissue composition adjacent to lacunae.
Keywords Raman spectroscopy · Mineral:matrix · Carbonate:phosphate · Crystallinity · Collagen maturity · Osteocyte · 
Perilacunar
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Introduction
Osteoporosis is characterized by low bone mass and 
increased risk of fracture. Current approved treat-
ments include both anti-resorptive and anabolic agents, 
such as parathyroid hormone (PTH), abaloparatide and 
romosozumab. The association of these treatments with 
improved bone mineral density (BMD) and bone quality, 
and the mechanisms by which they reduce risk of spine 
and hip fracture, has come under intense study. Strong 
anti-resorptives, like bisphosphonates (BPs), reduce bone 
resorption and formation, while increasing cortical thick-
ness, cortical area, and cortical strength [1]. When com-
bined, these effects may explain the reduction in fracture 
risk [2]. In contrast, PTH increases bone resorption and 
formation, while increasing cortical thickness, cortical 
area, and cortical strength [3]. The reduction in fracture 
risk, despite the opposite tissue level effects of anti-resorp-
tives and PTH on bone resorption and bone formation, 
has motivated the use of sequential therapies with the two 
types of agents with the goal of producing better results 
than with either monotherapy. Preclinical studies have 
demonstrated that sequential anti-resorptive and anabolic 
therapies improve trabecular bone mass, microarchitec-
ture, and strength, as well as cortical area, thickness, and 
strength [4, 5]. Clinical studies in osteoporotic patients 
given sequential anti-resorptive and anabolic therapies 
show that bone formation markers and spine and hip BMD 
improve more than with either monotherapy [2]. Although 
the effects of sequential anti-resorptive and anabolic thera-
pies on the mechanical and microarchitectural properties 
of bone have been investigated, the effects of such sequen-
tial therapy on bone tissue composition at the collagen and 
mineral level are unknown.
Approaches to studying mineral and/or collagen in 
bone tissue include scanning electron microscopy (SEM), 
nanoindentation, synchrotron X-ray computed microto-
mography, Fourier transform infrared (FTIR) spec-
troscopy, and Raman spectroscopy (RS). FTIR and RS 
quantify bone composition by calculating peak area and 
intensity ratios representing vibrational modes specific to 
mineral and collagen. The primary endpoints measured 
by FTIR and RS are mineral:matrix ratio, representing the 
extent of collagen mineralization; carbonate:phosphate 
ratio, representing the extent of carbonate substitution 
into the hydroxyapatite crystal lattice; crystallinity, rep-
resenting hydroxyapatite crystal size and stoichiometric 
perfection; and collagen maturity, representing the ratio 
of mature trivalent to immature divalent crosslinks [6].
Strong anti-resorptives reduce bone turnover and 
increase non-enzymatic crosslinking of the collagen 
matrix [7]. Bone structural units (BSUs) accumulate 
mineral throughout their lifespan. The reduced turnover 
rate caused by anti-resorptives increases the lifespan of 
individual BSUs, prolonging the time during which they 
accumulate mineral, causing them to reach a higher level 
of mineralization than is seen at normal turnover rates 
[8]. Alendronate, a strong anti-resorptive, alters bone qual-
ity in postmenopausal women by changing bone mineral 
properties, modulus, and microhardness [9]. Synchro-
tron small-angle X-ray scattering and wide-angle X-ray 
diffraction, FTIR spectroscopy, and advanced glycation 
end-products (AGEs) assessment of cortical bone tis-
sue showed increased non-enzymatic crosslinking of the 
collagen matrix in alendronate-treated female dogs [7]. 
Mild anti-resorptive agents like raloxifene also appear to 
increase bone matrix mineralization [10]. In summary, 
anti-resorptives increase tissue mineral content, decrease 
crystallinity, and increase non-enzymatic crosslinking. In 
contrast, PTH appears to decrease crystallinity, collagen 
maturity [11], and AGEs [12]. Like their complementary 
effects on turnover, the complementary effects of anti-
resorptives and PTH on bone tissue composition suggest 
that sequential therapy with anti-resorptive and anabolic 
agents may yield bone quality superior to either mono-
therapy alone.
Changes in whole-bone cross-sectional geometry, trabec-
ular morphology, and tissue mechanical properties with anti-
resorptive and anabolic therapies may also alter mechani-
cal signals detected by osteocytes, which could then alter 
their surrounding matrix in an adaptive response to their 
new mechanical environment. Structural changes with anti-
resorptive and anabolic treatment in cortical and trabecular 
compartments alter whole-bone stiffness and distribution of 
loads between compartments, thereby altering the macro-
scopic strains in the bone [13]. In addition to changing bone 
composition through their influence on bone turnover, bone-
active agents may also alter tissue hardness and modulus by 
changing the microscopic mechanical environment in bone 
tissue near the osteocyte [9]. Young’s modulus of bone tis-
sue near osteocyte lacunae is lower than in more distant bone 
tissue [14]. Previous studies report changes in osteocytes of 
rats given continuous PTH [15], and in bone tissue compo-
sition surrounding osteocytes with intermittent PTH [16], 
along with diffusion of BPs into the canalicular network 
[17]. It is well-documented that osteocytes are capable of 
removing and replacing the perilacunar bone matrix during 
lactation [18–20]. These results suggest that osteocytes alter 
the properties of their surrounding tissue, a process which 
may be influenced by sequential anti-resorptive and anabolic 
therapies. Therefore, therapy-related changes to both bone 
structure and tissue mechanical properties may occur, alter-
ing mechanical signals perceived by osteocytes [21].
We hypothesize that sequential anti-resorptive and ana-
bolic therapy in estrogen deficient, osteopenic rats alters 
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bone matrix composition adjacent to and far from osteocyte 
lacunae through its actions on osteocytes. When planning to 
study the effects of osteocytes on bone matrix composition, 
one must recall that bone remodeling is a process that affects 
bone matrix composition by altering tissue age. Thus, to 
obtain the clearest possible data about osteocyte effects on 
bone matrix composition, it would be advantageous to study 
bone tissue that is not influenced by bone remodeling. Since 
cortical bone in the rat long bone experiences no Haversian 
remodeling, we chose to study two bone matrix regions sur-
rounding osteocytes (perilacunar and non-perilacunar bone 
matrix) in the central long bone cortex. The objectives of 
this study were to determine: (1) the effect of treatments on 
cortical bone tissue composition by comparing the mineral 
and collagen matrix properties in adult, osteopenic, ova-
riectomized (OVX) rats given sequential or monotherapy 
with anti-resorptive agents and PTH; and (2) whether treat-
ment differentially affects composition within the cortex by 
comparing the mineral and collagen matrix properties in the 
perilacunar and non-perilacunar bone matrix regions.
Materials and Methods
Animals and Experimental Procedures
The bones examined here are a randomly selected sub-
set of those from a previously reported experiment [4, 5]. 
Six-month-old female OVX (N = 37) or Sham-operated 
Sprague–Dawley rats (N = 6) were purchased from Harlan 
Laboratories (Livermore, CA, USA). The study protocol was 
approved by the University of California Davis Institutional 
Animal Care and Use Committee.
All OVX rats were allowed to develop trabecular osteo-
penia of the distal femur and lumbar vertebral body for 
8 weeks, then randomized into seven groups that represent 
traditional long-term osteoporosis monotherapies or real-
world osteoporosis therapies that begin with frontline anti-
resorptive therapy that switches to either anabolic therapy 
or a drug holiday and then returns to the initial anti-resorp-
tive therapy. For 90 days (Period 1), OVX rats were treated 
with either: (a) vehicle (V, normal saline), 1 ml/kg/dose, 
three times per week by subcutaneous (SC) injection (Life 
Technologies); (b) parathyroid hormone [P, h-PTH (1–34) 
(human) acetate], 25 µg/kg/dose, 5 × /week SC (Bachem 
Biosciences, Inc., Torrance, CA, USA); (c) alendronate 
[A, 25 µg/kg/dose, 2 × /week SC (Sigma-Aldrich Corp., 
St. Louis, MO, USA)]; or (d) raloxifene [R, 5 mg/kg/dose, 
3 × /week by oral gavage (Sigma-Aldrich Corp., St. Louis, 
MO, USA)]. After Period 1, rats were switched to their sec-
ond treatment regimen. After a total of 180 days (end of 
Period 2), rats were switched to their third treatment regi-
men (Period 3). After a total of 270 days (end of Period 
3), corresponding to ~ 4–6 years of treatment in humans (6 
trabecular bone remodeling cycles), all rats were euthanized 
by  CO2 inhalation and necropsied. The groups are desig-
nated by the initial (V, P, A, or R) of the treatment applied 
during each period: VVV, PVV, RRR, RPR, AAA, AVA, 
and APA. Each treatment period involved only monotherapy. 
No two treatments were ever given simultaneously, mean-
ing that combination treatment never occurred. Following 
euthanasia, the left tibiae were dissected free, wrapped in 
saline-soaked gauze, and frozen at − 20 °C. The number of 
samples from each group is in parentheses: VVV (N = 7), 
PVV (N = 5), RRR (N = 5), RPR (N = 5), AAA (N = 5), AVA 
(N = 5), and APA (N = 5).
Raman Spectroscopy Analysis
A uniform specimen of 1.5 mm thickness was prepared from 
the proximal one-third of each left tibia (Fig. 1a), by making 
two parallel frontal plane cuts with a low-speed bone saw 
(Isomet; Buehler Co., Lake Bluff, IL, USA). The posterior 
face of the 1.5 mm section was polished under water with 
1200 grit SiC paper to create a smooth surface and then 
ultrasonicated in deionized water to remove all debris. The 
section was mounted in a Petri dish with the anterior surface 
facing down. For RS, the Petri dish was filled with deion-
ized water to submerge the specimen, and RS measurements 
of bone tissue surrounding osteocyte lacuna located in the 
central one-third region (relative to the periosteal and endo-
cortical surfaces) of the lateral cortex 8–12 mm from the 
proximal end of the tibia were carried out (blue rectangle, 
Fig. 1a).
Raman spectra were collected in 1 μm increments along 
a linear path beginning ~ 1 μm from the lacunar wall and 
ending 20 µm from the lacunar wall (Fig. 1b). Raman lin-
ear scans were performed on both the right and left side of 
osteocyte lacunae, and four to five osteocyte lacunae were 
investigated for each rat. Care was taken to be sure that no 
portion of any linear path passed within 20 µm of a neigh-
boring lacuna. Raman spectra were separated into two bone 
matrix regions as previously reported: (1) the perilacunar 
region (1–5 µm from the lacunar wall) [14, 16, 22]; and (2) 
the non-perilacunar region (16–20 µm from the lacunar wall) 
[14]. Thus, 40–50 Raman spectra were collected from each 
rat in each tissue region.
Spectra were obtained using a Raman microscope 
(LabRam HR 800 Horiba JobinYvon), with a helium–neon 
laser (633  nm) and a 60 × water immersion objective 
(NA = 0.9; Olympus). Raman spectra (Fig. 1c) and were 
collected over the range 800–1800 cm−1 with a spectral 
resolution of 0.25 cm−1 and spatial resolution of ~ 1.5 µm 
with 90 s acquisition times. All subsequent spectral analysis 
was performed using custom code (Matlab, The Mathworks, 
Inc., Natick, MA, USA). Each spectrum was background 
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subtracted, baseline corrected, and normalized against the 
maximum intensity of the δ  CH2 peak (1446 cm−1) [23].
Raman spectra were analyzed to determine the follow-
ing endpoints: mineral:matrix ratio, carbonate:phosphate 
ratio, collagen maturity, and mineral crystallinity [23]. Inte-
grated areas of the mineral ν1  PO43− (930–980 cm−1) and 
ν1CO32− (1050–1100 cm−1) peaks, and the collagen matrix 
amide III peak (1250–1300 cm−1) were calculated [24, 25] 
along with the intensities of the collagen matrix amide I 
peak at 1660 cm−1 and 1690 cm−1. The mineral:matrix ratio 
was calculated as the peak area ratio of ν1  PO43−/amide III 
[6]. The carbonate:phosphate ratio was calculated as the 
peak area ratio of ν1  PO43−/ν1CO32−. Crystallinity was cal-
culated as the inverse of the full width at half-maximum 
(FWHM) intensity of the ν1  PO43− peak at 960 cm−1. Col-
lagen maturity, recently validated with high performance 
liquid chromatography [26], was calculated from the inten-
sity ratio of amide I peaks of 1660 cm−1 and 1690 cm−1. For 
each rat, mean Raman parameters were calculated for each 
tissue region.
To examine the spatial variation of bone tissue compo-
sition for each rat, the FWHM of the distribution of each 
Raman endpoint, from spectra within tissue of the same 
region (perilacunar and non-perilacunar bone matrix) was 
calculated for each rat and combined to generate histograms 
of all four Raman parameters. The FWHM of the Gaussian 
curve fit to the endpoint distribution was used to assess com-
positional heterogeneity (Supplemental Fig. 1).
Statistical Analysis
Mean Raman outcomes were analyzed using a linear mixed 
model with (1) fixed effects of treatment and bone region 
(perilacunar and non-perilacunar) and the interaction 
between treatment and region; and (2) a random effect of rat 
to account for multiple spectra collected within each animal. 
Multiple comparisons were performed for the fixed effects 
of treatment and region using a Tukey post-hoc test with a 
Tukey correction for multiple comparisons. All values are 
expressed as mean ± SD. A significance level of P < 0.05 was 
used for all analyses.
Results
Effect of Treatment on Bone Tissue Composition
Tissue properties of the Sham group did not differ from 
those of the OVX group (VVV, Fig. 2a–d). Mean colla-
gen maturity of the combined perilacunar and bone matrix 
regions was greater in rats treated with raloxifene monother-
apy than in OVX (VVV, RRR + 12.4% vs. VVV; P < 0.01, 
Fig. 2d). Mean crystallinity was lower in rats given RPR 
sequential therapy versus OVX (VVV, RPR − 1.7% vs. VVV; 
P < 0.01, Fig. 2c).
Overall, sequential treatment with an anti-resorptive 
followed by PTH followed by an anti-resorptive lowered 
collagen maturity relative to monotherapy. Mean collagen 
maturity was lower in rats given sequential therapy that 
included alendronate followed by PTH followed by alen-
dronate than with alendronate monotherapy (APA − 11% vs. 
AAA, P = 0.02, Fig. 2d). Mean collagen maturity was also 
lower in rats given sequential therapy that included ralox-
ifene followed by PTH followed by raloxifene versus ralox-
ifene monotherapy (RPR − 8.5% vs. RRR, P = 0.03, Fig. 2d). 
Furthermore, APA rats had lower collagen maturity relative 
Fig. 1  Whole-bone and tissue level regions investigated by Raman 
spectroscopy (RS). a A 1.5-mm- thick section (hatched area) was 
removed from the proximal one-third of the tibia, by making two 
parallel frontal plane cuts (labeled 1 and 2). Spectra were collected 
from the central half of the lateral cortex 8–12 mm from the proximal 
end of the tibia (blue rectangle). b SEM image of an osteocyte lacuna 
(orange oval) and surrounding bone, showing a 20-µm-long linear 
RS measurement path (red dotted line, upper left). The third perpen-
dicular line on the path is 20 µm from the lacunar wall. Five evenly 
spaced measurements were made at 1–5  µm from the lacunar wall 
(perilacunar region) and at 16–20 µm from the lacunar wall (non-per-
ilacunar bone matrix region). c Representative Raman spectrum of rat 
cortical bone with the relevant mineral peak areas (v1  PO43− and v1 
 CO32−) and matrix peak area (amide III) shown in blue, the v1  PO43− 
peak FWHM shown as a yellow horizontal line, and the peak intensi-
ties at 1660 cm−1 and 1690 cm−1 shown in red and orange, respec-
tively
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to RRR monotherapy (− 12%, P < 0.01, Fig. 2d). Finally, 
sequential treatment altered the distributions of collagen 
maturity in a subset of treatment groups (see Supplemental 
Material).
Effect of Treatment on Distribution of Collagen 
Maturity
The distribution of collagen maturity narrowed with RPR 
sequential treatment relative to RRR monotherapy (− 38%, 
P = 0.02, Fig. 3). Bone tissue from rats receiving APA treat-
ment had a narrower distribution of collagen maturity than 
those receiving raloxifene monotherapy (− 44% vs. RRR, 
P < 0.01) and tended to have a narrower distribution of col-
lagen maturity than those receiving PVV treatment (− 36% 
vs. PVV, P = 0.09, Fig. 3).
Effect of Tissue Region on Bone Tissue Composition
The composition of the perilacunar region differed from 
that of the non-perilacunar bone matrix region. Differ-
ences between the perilacunar and non-perilacunar regions 
represent differences across all treatment groups because no 
significant interactions between treatment and tissue region 
were observed for any endpoint. In the perilacunar region 
versus the non-perilacunar region, the mineral:matrix ratio 
was greater (+ 2.2%, P = 0.04; Fig. 4a) and collagen maturity 
was greater (+ 1.4%, P < 0.01; Fig. 4d). In the perilacunar 
region, the carbonate:phosphate ratio was lower (− 2.2%, 
P < 0.01, Fig.  4b) and crystallinity was lower (− 0.3%, 
P < 0.01, Fig. 4c).
Discussion
Current approved treatments for osteoporosis include anti-
resorptive therapies that slow bone resorption and bone for-
mation and anabolic therapies that stimulate bone forma-
tion. Both types of monotherapy reduce risk of osteoporotic 
fracture. While most studies have focused on bone mass and 
density, biomechanical, and/or architectural changes brought 
about by these agents, this study evaluated localized micro-
scale measures of bone composition around osteocytes in 
non-remodeling bone that underlie the above macro-level 
Fig. 2  Mean Raman spectroscopic parameters demonstrating the 
fixed effect of treatment, separated by treatments. The mineral:matrix 
ratio (a), carbonate:phosphate ratio (b), mineral crystallinity (c), and 
collagen maturity (d) are plotted. *P0.05. Bar heights and error bars 
indicate mean ± SD, respectively. VVV vehicle–vehicle–vehicle, PVV 
PTH–vehicle–vehicle, RRR raloxifene–raloxifene–raloxifene, RPR 
raloxifene–PTH–raloxifene, AAA alendronate–alendronate–alen-
dronate, AVA alendronate–vehicle–alendronate, APA alendronate–
PTH–alendronate. Perilacunar region = open box and non-perilacunar 
bone matrix region = hatched box. See Supplemental Table  1 for 
P-values and percentage differences
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measures. Our design and general type of measurements bear 
some similarity to recent publications [27, 28]. We treated 
osteopenic, OVX rats in three consecutive periods of three 
months each with different sequences of single osteoporosis 
treatment agents. We used RS to assess local bone chemis-
try surrounding osteocyte lacunae to determine differences 
in cortical bone material composition that could account 
for our previous observation that anti-resorptive therapies 
in combination with PTH result in higher bone mass and 
strength and better microarchitecture than any monotherapy 
[4, 5]. Sequential treatment with an anti-resorptive followed 
by PTH followed by the anti-resorptive produced lower col-
lagen maturity relative to sequential monotherapies and 
lower mineral crystallinity relative to untreated OVX con-
trols. The composition of the perilacunar region differed 
from that of the non-perilacunar bone matrix region. Based 
on these results and the a priori knowledge that osteocytes 
can remove and replace perilacunar mineral [14–16, 18–20], 
we speculate that sequential treatments with osteoporosis 
treatment agents cause osteocytes to alter bone tissue com-
position in their surrounding microenvironment to reduce 
collagen maturity without changing mineral:matrix ratio, 
carbonate:phosphate ratio, and crystallinity.
Effect of Treatment on Bone Tissue Composition
Sequential treatment with an anti-resorptive followed by 
PTH followed by an anti-resorptive predominantly affected 
the organic matrix phase, decreasing collagen maturity rel-
ative to monotherapy. Mean collagen maturity was lower 
with APA and RPR treatments versus their respective mon-
otherapy. These results suggest that sequential treatments 
that involve PTH and anti-resorptive therapies lead to col-
lagen with a lower ratio of mature trivalent crosslinks to 
immature divalent crosslinks [23, 29–32], consistent with 
stimulation of bone formation by PTH [2, 3]. This result is 
notable because it was obtained in cortical bone tissue that 
experiences no Haversian remodeling, raising the possibility 
that these therapies may cause osteocytes to change the com-
position of their surrounding bone independently of the bone 
age-related effects caused by differing turnover rates asso-
ciated with use of anti-resorptive and anabolic treatments.
Mineral composition also differed with sequential anti-
resorptive and anabolic treatments. Specifically, mean 
mineral crystallinity was 0.3% lower in rats given RPR 
sequential therapy than in OVX rats. This lower crystal-
linity corresponds to a decrease in hydroxyapatite crystal 
Fig. 3  Full width of half-maximum of the Gaussian fit to distribu-
tions of Raman spectroscopic parameters, separated by tissue region, 
including the a mineral:matrix ratio, b carbonate:phosphate ratio, c 
mineral crystallinity, and d collagen maturity. *P < 0.05. Bar heights 
and error bars indicate mean ± SD, respectively. VVV vehicle–vehi-
cle–vehicle, PVV PTH–vehicle–vehicle, RRR raloxifene–raloxifene–
raloxifene, RPR raloxifene–PTH–raloxifene, AAA alendronate–alen-
dronate–alendronate, AVA alendronate–vehicle–alendronate, APA 
alendronate–PTH–alendronate. Perilacunar region = open box and 
non-perilacunar bone matrix region = hatched box
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size and stoichiometric perfection. This result is consistent 
with lower mineral crystallinity after PTH treatment [11, 
33] and with maintained [34, 35] or lowered [9, 36] mineral 
crystallinity with anti-resorptive monotherapy. Addition-
ally, raloxifene is known to increase matrix bound water 
content, which may play a role in the altered mineral crys-
tallinity, although the exact nature of this interaction and 
the direction of the effect on crystallinity is unknown [37]. 
Despite these differences in mineral crystallinity, no differ-
ences were found in the mineral:matrix ratio, the extent of 
collagen mineralization, similar to results reported for anti-
resorptive monotherapy [9]. The lower mineral crystallin-
ity is most likely due to decreased stoichiometric perfection 
rather than decreased crystal size because the hydroxyapatite 
crystal width is correlated with tissue mineral content [38], 
and no differences in mineral:matrix ratio were observed [9]. 
This conclusion is further supported by the nominal increase 
in the carbonate:phosphate ratio in rats given RPR sequen-
tial therapy versus OVX controls because greater carbonate 
substitution into the crystal lattice decreases crystal size and 
stoichiometric perfection [39]. Again, this result is unique, 
because it was obtained in non-remodeling bone, and could 
make one speculate that these therapies cause osteocytes to 
change the composition of their surrounding bone.
It is well known that osteoporosis treatment agents can 
act through bone remodeling activity to change bone tissue 
composition [6, 34, 36, 40]. It is possible that tissue level 
mechanisms other than bone remodeling, such as osteo-
cyte activity, exist, that may also respond to osteoporosis 
treatment agents by changing bone tissue composition. The 
effects of these additional tissue level mechanisms on bone 
tissue composition are impossible to separate from those 
caused by changes in the hormonal environment or agents 
mediated through bone remodeling activity. Thus, our meas-
urements examine the effect of ovariectomy and osteopo-
rosis treatment agents on bone tissue composition around 
osteocytes in non-remodeling cortical bone. If an osteoporo-
sis treatment agent were to change bone tissue composition 
Fig. 4  Mean Raman spectroscopic parameters demonstrating 
the fixed effect of tissue region, separated by tissue region. The 
mineral:matrix ratio (a), carbonate:phosphate ratio (b), mineral crys-
tallinity (c), and collagen maturity (d) are re-plotted (vs. Figure  2) 
to clarify the relationship of the perilacunar and non-perilacunar 
bone matrix regions. *P0.05. Bar heights and error bars indicate 
mean ± SD, respectively. VVV vehicle–vehicle–vehicle, PVV PTH–
vehicle–vehicle, RRR raloxifene–raloxifene–raloxifene, RPR ralox-
ifene–PTH–raloxifene, AAA alendronate–alendronate–alendronate, 
AVA alendronate–vehicle–alendronate, APA alendronate–PTH–alen-
dronate. Perilacunar region = open box, non-perilacunar bone matrix 
region = hatched box
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in remodeling bone tissue, but not in non-remodeling tis-
sue, one would not only know that it acts by affecting bone 
remodeling activity, but could also legitimately speculate 
that they it does not affect other tissue level mechanisms 
like osteocyte activity. Our data, like many [28, 41, 42], 
but not others [43], show no differences in composition of 
cortical bone between Sham–OVX and OVX rats. On the 
other hand, data from non-human primate cortical bone 
remodeling sites, show that bone tissue composition differs 
in OVX and Sham–OVX animals in a bone site where both 
remodeling activity and osteocyte activity are ongoing [44, 
45]. Based on these data, it is apparent that estrogen defi-
ciency accelerates bone remodeling activity and changes 
bone composition. However estrogen deficiency does not 
cause osteocyte activity to change bone composition in non-
remodeling bone, leading one to consider the likelihood that 
bone remodeling activity, not osteocyte activity, is the tissue 
level mechanism through which estrogen deficiency affects 
bone tissue composition.
The combined results of our tissue level Raman com-
positional outcomes here with mechanical and microarchi-
tectural measures on whole bones [5] show that sequential 
anti-resorptive and PTH therapies improve bone quality at 
multiple levels. Sequential anti-resorptive and PTH therapies 
decrease tissue age by promoting new bone formation, based 
on collagen maturity outcomes [46], while these therapies 
also produce and maintain better bone mass, microarchi-
tecture, and strength than can be achieved by monotherapy 
[5]. Our data suggest that these therapies may also act by 
affecting bone composition around osteocytes.
Bone composition in rats that received PTH (1–34) 
during Period 1 or Period 2 still differs 90–180 days after 
the last exposure to PTH (1–34). Osteocyte lacunar size 
enlarges during lactation [47, 48] or PTH (1–34) treatment 
[15] within weeks and is maintained for the duration of the 
altered physiologic state. Few studies have provided data 
about bone composition after cessation of PTH (1–34). We 
speculate that after PTH (1–34) cessation, new mineralized 
tissue is deposited on the lacunar wall, reducing osteocyte 
lacunar size. Our data show that the bone tissue near osteo-
cytes retains a different composition for up to six months 
after cessation of PTH (1–34).
Region‑Specific Compositional Properties
A consequence of a heterogeneous distribution of composi-
tion within the bone tissue is a heterogeneous distribution 
of mechanical properties. At the cellular level, the osteocyte 
is believed to be the main mechanosensory cell in bone, 
orchestrating the actions of osteoclasts and osteoblasts in 
response to load-induced strain [49]. How the osteocyte 
perceives strain is largely unknown, but strain distribu-
tions within bone vary in a heterogeneous pattern, which 
are likely dependent upon the heterogeneous composition of 
bone [21]. One aspect of this heterogeneity is the bone tissue 
surrounding the osteocyte lacunae including perilacunar and 
non-perilacunar bone matrix regions, which play important 
roles in the strain environment experienced by the osteo-
cyte [50]. These regions may be functionally distinct in that 
under certain conditions, such as during lactation [47], exer-
cise [22], or PTH treatment [15, 16], the perilacunar region 
undergoes osteocyte-mediated remodeling, a localized pro-
cess that does not affect the non-perilacunar bone matrix 
tissue region [18–20]. The elastic modulus of the perilacunar 
region differs from that in the non-perilacunar bone matrix 
region [14, 51], which modulates the strain fields experi-
enced by osteocytes. Though we did not directly examine 
osteocytes for morphologic signs of treatment-related differ-
ences in activity, we speculate that the different bone com-
position outcomes following treatment may be an indicator 
of such activity. These studies, combined with our data, may 
indirectly suggest that bone tissue composition surround-
ing osteocytes is also altered by sequentially applied anti-
resorptive and anabolic osteoporosis treatment medications.
The bone mineral composition of the perilacunar region 
differed from that of the non-perilacunar bone matrix region. 
The perilacunar region had greater mean mineral:matrix 
ratio, lower crystallinity, greater mean collagen maturity, 
and lower mean carbonate:phosphate ratio (Fig. 4b) com-
pared to the non-perilacunar bone matrix region. These dif-
ferences suggest that though the perilacunar tissue is more 
highly mineralized, the mineral is also more chemically pure 
with less carbonate substitution into the crystal lattice.
These results differ somewhat from those reported in a 
recent study on the effects of intermittent h-PTH (1–34) on 
bone tissue composition in the perilacunar and non-perila-
cunar bone matrix region in intact mice. In parallel with 
our results, the prior study found no significant interaction 
between tissue region and treatment on bone tissue com-
position. In contrast to our findings, the prior study found 
decreased mineral:matrix ratio in the perilacunar region 
compared to the non-perilacunar bone matrix region across 
both intermittent h-PTH (1–34) and vehicle treatments. 
Several factors could potentially contribute to the observed 
differences, including differing definitions of the non-per-
ilacunar bone matrix region (10–15 m from the lacunar wall 
[16] vs. 16–20 m here), the estrogen deficient status of most 
of our groups, and intrinsic differences between the rat and 
mouse skeletons.
The greater tissue mineral content in the perilacunar 
region observed in the current study may reduce the ratio 
of globally applied strain to the local strain signal near 
the osteocyte. Differences in mineral and matrix proper-
ties between the perilacunar bone and non-perilacunar 
matrix suggest complex region-specific changes that may 
be associated with perilacunar osteocyte activity. The lower 
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carbonate:phosphate ratio in the perilacunar region vs. the 
non-perilacunar matrix indicates more recent nucleation of 
the mineral crystals and the possibility of increased perila-
cunar osteocyte activity [46]. In contrast, the greater relative 
concentration of mature trivalent crosslinks in the perilacu-
nar region versus the non-perilacunar matrix indicates the 
presence of more mature collagen. Together these results 
mean that one could speculate that perilacunar osteocyte 
activity promotes turnover of the mineral crystals while 
allowing continued maturation of the collagen matrix [46].
Since we studied non-remodeling bone and made no 
direct studies of osteocytes, we speculate that the modest 
compositional differences seen here arise from the ability 
of osteocytes to alter their microenvironment [15, 18–20, 
51]. The osteocyte microenvironment appears to influence 
predominantly the mineral phase of bone. Osteocytes add 
and remove mineral in the perilacunar bone [18–20, 51, 52]. 
Our results may provide additional evidence that osteocyte-
based deposition and removal of mineral is more promi-
nent in perilacunar bone matrix than in more distant bone 
matrix, because bone composition in the perilacunar bone 
matrix differs from that in the more distant bone matrix. 
The greater mineral:matrix ratio observed in the perilacu-
nar region relative to the non-perilacunar bone matrix may 
arise from the specialized ability of the osteocyte to trans-
fer calcium between the serum and the perilacunar region 
[52]. The lower carbonate:phosphate ratio in the perilacu-
nar region is consistent with an acid phosphatase-mediated 
dissolution of the mineral phase in an acidic environment, 
because mineral acid phosphate content increases with 
decreased carbonate:phosphate ratio and pH [51]. The low 
carbonate:phosphate ratio is consistent with the increase 
in mineral solubility in the perilacunar region relative to 
the non-perilacunar bone matrix region and suggests the 
presence of newly formed mineral [52]. Although the 2.2% 
greater tissue mineral content in perilacunar bone appears 
inconsistent with the observation that the elastic modulus of 
the perilacunar tissue is 3–13% less than the non-perilacunar 
bone matrix in OVX rats, other aspects of bone composition 
could play a role. Specifically, the ability of an osteocyte to 
increase the size of canaliculi may increase the microporos-
ity of bone tissue in the perilacunar region, which would 
decrease the indentation modulus, without altering the 
mineral:matrix ratio [48]. Both observations are consistent 
with a scenario in which the osteocyte creates a gradient of 
increasing tissue mineral content in the 20 µm of surround-
ing bone matrix.
These results suggest that incorporating PTH with 
raloxifene in sequential therapy produces bone tissue with 
a more spatially homogeneous ratio of mature trivalent 
crosslinks to immature divalent crosslinks. This result 
is consistent with previous reports that anti-resorptive 
monotherapy narrows the distributions of compositional 
properties [38, 40]. This result is unique, because it was 
obtained in non-remodeling bone, and appears to indicate 
that these therapies cause osteocytes to change the compo-
sition of their surrounding bone, an alteration that may be 
more difficult to detect in trabecular bone due to its higher 
remodeling rate.
The design of the experiment [4, 5] has a number of 
strengths that include evaluating the effect on bone mass 
and quality of sequential therapies with medications that 
have opposite tissue level mechanisms of action and are pre-
scribed by clinicians to reduce fracture risk in postmeno-
pausal women. In addition, we evaluated cortical bone from 
both anti-resorptive and anabolic sequential treatments using 
a rat model of estrogen deficiency osteopenia with trabecular 
bone behavior similar to that in women with postmenopausal 
osteoporosis [4]. We chose to evaluate cortical bone to limit 
the effect of local variations in tissue age that are apt to be 
more marked in trabecular bone than in cortical bone, due 
to the higher rate of remodeling in trabecular than cortical 
bone. Rat cortical bone is, for these measurements, likely to 
be a reasonable model for human cortical bone. Although 
it is often stated that rat long bone cortical bone does not 
remodel and human long bone cortical bone does remodel, 
implying that they are quite different, the absolute remod-
eling rates, 0% (or “not at all”) in rats and 3% in humans 
[53, 54], are very similar. The overall interpretation is that 
cortical bone in the rat long bone, that resides in a species 
that lives two years as an adult, undergoes no remodeling 
during the two years of life, while human long bone cortical 
bone, that resides in a species that lives roughly 60 years as 
an adult, undergoes remodeling once every 30 years. Corti-
cal bone in both species is thus very inactive. Therefore, our 
cortical bone measurements in rats are certain to represent 
bone tissue that has not been recently remodeled, and it is 
highly likely that cortical bone measurements from humans 
would also come from bone tissue that has not been recently 
remodeled. On this basis, the cortical bone composition 
measurements performed in these experiments have a good 
chance to be relevant to clinical studies.
However, there are also several weaknesses. We evaluated 
bone composition only after 270 days. Evaluating earlier 
samples may provide additional information about changes 
in the bone matrix caused by the individual treatments (e.g., 
immediately after cessation of PTH). In addition, we did not 
evaluate trabecular bone, due to its high rate of remodeling 
that could easily obscure effects on bone composition that 
are mediated through tissue level mechanisms other than 
remodeling activity, such as osteocyte activity and physi-
ological changes in mineral metabolism. Finally, although 
we were certain of the distance of bone tissue from the oste-
ocyte lacunar wall in the plane of the linear measurement 
path, it is not possible to know the location of any osteocyte 
lacunae that existed in the 10 µm of bone tissue that was 
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removed just adjacent to the plane of tissue that contained 
the linear paths.
In summary, we used RS to analyze differences in corti-
cal bone matrix composition in female rats that had been 
treated with either monotherapies or sequential therapies 
with alendronate, raloxifene and/or h-PTH (1–34). We 
identified differences in the organic matrix composition 
with sequential therapies which may reflect differences in 
bone quality. Also, we identified compositional differences 
in the mineral and organic matrix phase surrounding osteo-
cyte lacunae, potentially implicating osteocytes in altering 
the local tissue and treatments in changing that osteocyte 
activity. Additional studies of considerable interest include 
direct studies of osteocyte activity and how osteocytes’ abil-
ity to perceive strain and how the propagation of microc-
racks change are related to changes in the composition of the 
perilacunar matrix. Additional studies with clinical cortical 
bone samples are warranted to determine if these results can 
be translated to inform health care providers about cortical 
bone quality changes in their patients treated sequentially 
with anti-resorptive and anabolic agents.
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